Rosacea
Conditions
Keywords
rosacea, mast cell stabilizers, tranilast, minocycline, treatment, clinical research
Brief summary
Rosacea is a chronic inflammatory skin disease with a complex pathogenesis involving multiple factors. Currently, the treatment of rosacea remains highly challenging. Mast cells, as key participants in the pathogenesis of rosacea, have been shown to alleviate rosacea symptoms with some topical, oral, and injectable mast cell stabilizers in recent years. Tranilast stabilizes mast cells and basophils by acting on their cell membranes and preventing their degranulation. Tranilast has been used in the treatment of various skin disease, such as hypertrophic scars and atopic dermatitis. Minocycline is a first-line treatment for rosacea, and low-dose minocycline treatment (50mg/day) is believed to have anti-inflammatory effects without antibacterial effects, thus minimizing the dysbiosis and bacterial resistance caused by antibiotic use. Therefore, this study aims to investigate the effectiveness and safety of combining mast cell stabilizer tranilast with low-dose minocycline treatment for rosacea, providing new treatment options and insights for rosacea patients.
Detailed description
Rosacea is a chronic inflammatory skin disease with a complex pathogenesis involving multiple factors. Currently, the treatment of rosacea remains highly challenging. In the skin, mast cells are located in the dermis near nerve endings and blood vessels, playing a crucial role in inflammatory responses. Mast cells, as key participants in the pathogenesis of rosacea, have been shown to alleviate rosacea symptoms with some topical, oral, and injectable mast cell stabilizers in recent years. Tranilast stabilizes mast cells and basophils by acting on their cell membranes and preventing their degranulation. Tranilast has been used in the treatment of various skin disease, such as hypertrophic scars and atopic dermatitis. Minocycline is a first-line treatment for rosacea, and low-dose minocycline treatment (50mg/day) is believed to have anti-inflammatory effects without antibacterial effects, thus minimizing the dysbiosis and bacterial resistance caused by antibiotic use. However, there is currently a lack of clinical studies evaluating the efficacy and safety of combined treatment with tranilast and minocycline for rosacea. Therefore, this study aims to investigate the effectiveness and safety of combining mast cell stabilizer tranilast with low-dose minocycline treatment for rosacea, providing new treatment options and insights for rosacea patients.
Interventions
DRUGminocycline
The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
DRUGtranilast
The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
Sponsors
Second Affiliated Hospital of Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Males and nonpregnant females, aged 18-60 years old; 2. Diagnosed with erythematotelangiectatic or papulopustular rosacea, with an investigator' s global assessment of 3-5; 3. Patients with good cognitive function and normal mental status; 4. Patients with good communication skills; 5. Voluntary participation in the study and signing of informed consent form.
Exclusion criteria
1. Allergy to any component of tranilast capsules; 2. Allergy to any component of minocycline capsules; 3. History of systemic medication for rosacea treatment within the past month; 4. Pregnancy or lactation; 5. Presence of severe primary diseases in addition to rosacea, such as cardiovascular system, cerebrovascular system, digestive system, urinary system, hematopoietic system diseases, or systemic failure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| lesion counts | From enrollment to week 12 | The counts of skin lesions, including papules, pustules, and papulopustules, was used to evaluate the changes of facial inflammatory skin lesions before and after treatment. |
| Clinician's Erythema Assessment score | From enrollment to week 12 | The name of the scale is Clinician's Erythema Assessment. It was used to evaluate the change of persistent facial erythema before and after treatment. The score on the Clinician's Erythema Assessment scale ranges from 0 to 9, with higher scores indicating more severe persistent erythema on the patient's face. |
| Global Flushing Severity Scale score | From enrollment to week 12 | The name of the scale is Global Flushing Severity Scale. It was used to evaluate the change of facial flushing symptoms before and after treatment. The score on the Global Flushing Severity Scale ranges from 0 to 10, with higher scores indicating more severe symptoms of facial flushing. |
| Global Acne Grading System score | From enrollment to week 12 | The name of the scale is Global Acne Grading System. It was used to evaluate the changes of facial inflammatory skin lesions before and after treatment. The Global Acne Grading System score ranges from 0 to 32, with higher scores indicating more inflammatory lesions on the patient's face. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| patient satisfaction evaluation | week 12 | Patient satisfaction was evaluated as very satisfied, satisfied, relatively satisfied and dissatisfied. |
| Dermatology Life Quality Index score | week 0 and12 | The name of the scale is Dermatology Life Quality Index. It was used to assess the changes in quality of life before and after treatment. The Dermatology Life Quality Index score ranges from 0 to 29, with higher scores indicating a greater impact of the disease on the patient's quality of life. |
| melanin index | From enrollment to week 12 | Use non-invasive skin analyzer to measure the melanin index on the patient's facial skin at each follow-up visit. |
| erythema index | From enrollment to week 12 | Use non-invasive skin analyzer to measure the erythema index on the patient's facial skin at each follow-up visit. |
| transepidermal water loss | From enrollment to week 12 | Use non-invasive skin analyzer to measure the transepidermal water loss on the patient's facial skin at each follow-up visit. |
Countries
China
Outcome results
None listed